Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03801902 |
Title | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial |
Recruitment | Suspended |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |